Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
US Army
Citi
Accenture
Daiichi Sankyo
Queensland Health
McKinsey
Argus Health
Fuji
Merck

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,618,172

« Back to Dashboard

Which drugs does patent 8,618,172 protect, and when does it expire?


Patent 8,618,172 protects TEKTURNA HCT and is included in one NDA. There has been one Paragraph IV challenge on Tekturna HCT.

This patent has thirty patent family members in twenty-four countries.

Summary for Patent: 8,618,172

Title:Galenical formulations of organic compounds
Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations of these.
Inventor(s): Willmann; Matthias (Basel, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:12/304,244
Patent Claim Types:
see list of patent claims
Compound; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Noden PharmaTEKTURNA HCTaliskiren hemifumarate; hydrochlorothiazideTABLET;ORAL022107-001Jan 18, 2008RXYesNo► Subscribe► Subscribe► SubscribeY
Noden PharmaTEKTURNA HCTaliskiren hemifumarate; hydrochlorothiazideTABLET;ORAL022107-002Jan 18, 2008RXYesNo► Subscribe► Subscribe► SubscribeY
Noden PharmaTEKTURNA HCTaliskiren hemifumarate; hydrochlorothiazideTABLET;ORAL022107-003Jan 18, 2008RXYesYes► Subscribe► Subscribe► SubscribeY
Noden PharmaTEKTURNA HCTaliskiren hemifumarate; hydrochlorothiazideTABLET;ORAL022107-004Jan 18, 2008RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,618,172

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0612540.5Jun 23, 2006
PCT Information
PCT FiledJune 21, 2007PCT Application Number:PCT/EP2007/005476
PCT Publication Date:December 27, 2007PCT Publication Number: WO2007/147596

International Patent Family for Patent: 8,618,172

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2009101971► Subscribe
Peru09902012► Subscribe
Peru03732008► Subscribe
New Zealand572937► Subscribe
Norway20090262► Subscribe
Malaysia146779► Subscribe
Mexico2008016533► Subscribe
Morocco30527► Subscribe
South Korea101442272► Subscribe
South Korea20090021353► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Johnson and Johnson
Moodys
Express Scripts
McKinsey
Boehringer Ingelheim
Medtronic
Colorcon
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot